Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon

<div><p>Abstract Hepatitis C is a worldwide endemic disease. However, hepatitis C virus genotype 4 (HCV GT-4) has rarely been reported in Brazil. HCV GT-4 demonstrates high sustained virological response (SVR). Here, we report the case of a 62-year-old HCV GT-4 positive woman complaining of a headache, nausea, and arthralgia. The patient was treated according to the protocol for genotype 4 (12 weeks administration of 400mg sofosbuvir and 60mg daclatasvir daily) and achieved SVR. Although this is not an Amazonas autochthonous case, the presence of genotype 4 is rarely reported in the region.</p></div

Association of parasitemia with <i>TLR</i> and <i>CD14</i> polymorphisms in <i>Pv</i>-malaria patients.

<p>Association of parasitemia with <i>TLR</i> and <i>CD14</i> polymorphisms in <i>Pv</i>-malaria patients.</p

Genotype and allele frequencies of the TLRs and CD14 polymorphisms in patients with <i>Pv</i>-malaria and healthy controls.

<p>Genotype and allele frequencies of the TLRs and CD14 polymorphisms in patients with <i>Pv</i>-malaria and healthy controls.</p

Study and data analysis flow chart.

<p>We included 599 eligible participants from two cohort studies conducted in Amazonas. Of these, 274 healthy individuals without malaria history in the prior 12 months were included in the “Healthy Group” and 325 patients diagnosed with <i>Pv</i>-malaria infection were included in the “<i>Pv</i>-malaria Cases”. Parasitemia analysis was performed for 208 patients.</p

Clinical and demographic characteristics of the study population.

<p>Clinical and demographic characteristics of the study population.</p